GO:0032696 negative regulation of interleukin-13 production: Immune Regulation Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0032696 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of interleukin-13 (IL-13) production.
• IL-13 is a type 2 cytokine produced by Th2 cells, mast cells, and B lymphocytes, and its excessive production drives allergic inflammation and airway remodeling.
• Negative regulators of IL-13 production include CISH, CFTR, Linc00632, and miR-16, which act through distinct signaling and transcriptional mechanisms.
• Dysregulation of IL-13 production is implicated in asthma, atopic dermatitis, psoriasis, and cystic fibrosis-related airway inflammation.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of genes that negatively regulate IL-13 production.
• Understanding GO:0032696 supports development of therapeutics that restrain Th2-driven pathology without broadly immunosuppressing patients.
Description
Interleukin-13 (IL-13) is a central type 2 cytokine that orchestrates allergic inflammation, mucus hypersecretion, and airway hyperresponsiveness. Its production is tightly controlled at the transcriptional and post-transcriptional levels, and the Gene Ontology term GO:0032696, negative regulation of interleukin-13 production, captures any process that stops, prevents, or reduces the frequency, rate, or extent of IL-13 production. This term is essential for researchers because unrestrained IL-13 production underlies multiple chronic inflammatory diseases, and identifying the negative regulators provides therapeutic targets. IL-13 is synthesized by several cell types, including activated Th2 cells, mast cells, and B lymphocytes, and its secretion can be modulated by cytokines, microRNAs, long noncoding RNAs, and ion channels. For example, CISH acts as a negative regulator of IL-13-induced CCL26 production in lung fibroblasts, indirectly influencing the inflammatory milieu. CFTR negatively reprograms Th2 cell responses, and its potentiation restrains allergic airway inflammation, highlighting how a single gene can gate IL-13 production. This article integrates authoritative QuickGO annotation for GO:0032696 with verified PubMed literature to provide a research-grade overview of the mechanisms, key genes, disease relevance, and experimental models used to study negative regulation of IL-13 production. It is intended for immunologists, pulmonologists, and drug discovery scientists seeking to manipulate this pathway with precision.
negative regulation of interleukin-13 production At A Glance
| GO ID | GO:0032696 |
|---|---|
| GO term | negative regulation of interleukin-13 production |
| Ontology | biological_process |
| Synonym | down regulation of interleukin-13 production; down-regulation of interleukin-13 production; downregulation of interleukin-13 production; inhibition of interleukin-13 production; negative regulation of IL-13 production; negative regulation of interleukin-13 biosynthetic process; negative regulation of interleukin-13 secretion |
| Major function | Dampening IL-13 cytokine output to limit type 2 inflammation and associated tissue remodeling |
| Cellular context | Th2 cells, mast cells, B lymphocytes, lung fibroblasts, nasal epithelial cells |
| Key negative regulators | CISH, CFTR, Linc00632, miR-16 |
| Disease relevance | Asthma, atopic dermatitis, psoriasis, cystic fibrosis airway inflammation |
| Research methods | CRISPR KO/point mutation/knock-in/overexpression, RNA-seq, cytokine assays, flow cytometry |
What Is GO:0032696?
GO:0032696, negative regulation of interleukin-13 production, is a biological process that encompasses any mechanism that stops, prevents, or reduces the frequency, rate, or extent of interleukin-13 production. This includes negative regulation of IL-13 biosynthetic process and negative regulation of IL-13 secretion, as reflected in the synonym list. The term is used to annotate gene products that directly or indirectly dampen IL-13 output from cells such as T helper 2 cells, mast cells, and B lymphocytes.
Why Is negative regulation of interleukin-13 production Important in Cell Biology?
Negative regulation of interleukin-13 production is critical because IL-13 is a potent driver of allergic asthma, atopic dermatitis, and other type 2 inflammatory disorders, and its overproduction leads to mucus plugging, airway remodeling, and chronic itching. Understanding the endogenous brakes on IL-13 production can reveal new drug targets and biomarkers, as exemplified by CFTR potentiation that restrains allergic airway inflammation. Moreover, microRNAs and long noncoding RNAs that negatively regulate IL-13-induced responses provide additional layers of control that can be exploited therapeutically.
• IL-13 is a central mediator of type 2 inflammation in asthma and atopic dermatitis.
• Negative regulation prevents excessive mucus production and airway hyperresponsiveness.
• CISH dampens IL-13-induced CCL26 in lung fibroblasts, limiting eosinophil recruitment.
• CFTR negatively reprograms Th2 responses, linking ion channel function to IL-13 control.
• Linc00632 inhibits IL-13-induced inflammatory cytokines and mucus in nasal epithelium.
• miR-16 suppresses IL-13-induced NF-kB signaling and cytokine secretion.
• B lymphocytes produce IL-13 that regulates IgE, connecting negative regulation to allergy.
• Mast cells both produce and respond to IL-13, amplifying type 2 loops.
• Dysregulated IL-13 production is implicated in psoriasis and atopic dermatitis scratch injury.
• Targeting negative regulators may restore immune balance without broad immunosuppression.
What Happens During negative regulation of interleukin-13 production?
Initiation of negative signals
In simple terms: Cells receive signals that tell them to stop making IL-13.
Negative regulation of IL-13 production begins when extracellular or intracellular cues activate inhibitory pathways. For instance, CFTR activity in Th2 cells negatively reprograms their responses, and its potentiation restrains allergic airway inflammation. Similarly, CISH is a negative regulator of IL-13-induced CCL26 production in lung fibroblasts, indicating that cytokine-inducible SOCS proteins can feedback to limit IL-13-driven outputs. These initial signals set the stage for downstream transcriptional and post-transcriptional silencing.
Transcriptional and post-transcriptional suppression
In simple terms: The cell reduces the instructions and stability of IL-13 mRNA.
Once negative signals are engaged, transcription factors and noncoding RNAs can suppress IL-13 gene expression or degrade its mRNA. The long noncoding RNA Linc00632 inhibits IL-13-induced inflammatory cytokine and mucus production in nasal epithelial cells, demonstrating that lncRNAs can act as brakes on IL-13-mediated responses. MicroRNA-16 inhibits IL-13-induced inflammatory cytokine secretion and mucus production by suppressing the IκB kinase β/nuclear factor-κB pathway, indirectly reducing the inflammatory amplification that sustains IL-13 production.
Secretion blockade and protein-level control
In simple terms: Even if some IL-13 is made, its release can be blocked.
Negative regulation can also occur at the level of secretion. The synonym 'negative regulation of interleukin-13 secretion' indicates that processes preventing IL-13 release from producer cells are included in GO:0032696. Mast cells produce and respond to IL-13, and their secretion can be modulated by autocrine and paracrine loops. B lymphocytes synthesize IL-13 that regulates IgE production, and this synthesis is subject to regulatory control. Thus, blocking vesicular trafficking or promoting intracellular retention can reduce extracellular IL-13 levels.
Feedback loops and resolution of inflammation
In simple terms: The system resets itself to avoid chronic inflammation.
Negative regulation of IL-13 production is integral to resolving type 2 inflammation. CISH-mediated feedback in lung fibroblasts limits CCL26 production, which would otherwise recruit eosinophils. CFTR potentiation restrains allergic airway inflammation, suggesting that restoring negative regulators can break the cycle of chronic IL-13 production. In atopic dermatitis and psoriasis, epidermal scratch injury can exacerbate IL-13-driven pathology, underscoring the need for effective negative regulation.
Key Genes Involved in GO:0032696 negative regulation of interleukin-13 production
The following genes and noncoding RNAs have been experimentally linked to negative regulation of IL-13 production or IL-13-driven inflammatory outputs.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CISH | Negative regulator of IL-13-induced CCL26 in lung fibroblasts | Feedback control of eosinophil recruitment |
| CFTR | Negatively reprograms Th2 cell responses; potentiation restrains allergic airway inflammation | Links ion channel function to IL-13 regulation |
| Linc00632 | Inhibits IL-13-induced inflammatory cytokine and mucus production in nasal epithelial cells | lncRNA brake on type 2 inflammation |
| miR-16 | Suppresses IKKβ/NF-κB pathway, reducing IL-13-induced cytokine secretion | Post-transcriptional control of IL-13 responses |
| IL13 | Type 2 cytokine; its production is the target of negative regulation | Central effector of allergic inflammation |
| IL4 | Cytokine that synergizes with IL-13 in type 2 responses | Co-regulator of Th2 inflammation |
| IL4R | Receptor for IL-4 and IL-13; signaling modulates production | Target for blocking type 2 cytokines |
| STAT6 | Transcription factor downstream of IL-4/IL-13; feedback regulation | Mediator of IL-13-induced gene expression |
| SOCS1 | Cytokine signaling suppressor; potential feedback inhibitor | Negative regulator of cytokine signaling |
| SOCS3 | Cytokine signaling suppressor; potential feedback inhibitor | Modulates IL-13 signaling |
| NFKB1 | NF-κB subunit; pathway suppressed by miR-16 | Inflammatory transcription factor |
| IKBKB | IKKβ kinase; target of miR-16 suppression | Upstream activator of NF-κB |
| CCL26 | Eotaxin-3; induced by IL-13 and negatively regulated by CISH | Eosinophil chemoattractant |
| MUC5AC | Mucin gene induced by IL-13; suppressed by Linc00632 and miR-16 | Mucus production marker |
| ELP3 | Loss blocks intestinal tuft cell differentiation via mTORC1-Atf4 axis | Epigenetic regulator of epithelial differentiation |
| mTORC1 | Signaling hub integrating nutrient and immune cues | Potential upstream regulator of IL-13 responses |
| ATF4 | Stress-responsive transcription factor downstream of mTORC1 | Integrated stress response mediator |
How Is negative regulation of interleukin-13 production Regulated?
Negative regulation of IL-13 production is controlled by multiple layers of feedback. Cytokine-inducible SOCS proteins such as CISH can dampen IL-13 signaling and downstream outputs in lung fibroblasts. The mTORC1-Atf4 axis has been implicated in epithelial differentiation and may influence type 2 immune responses, as loss of Elp3 blocks intestinal tuft cell differentiation via this axis. CFTR activity negatively reprograms Th2 cells, and its pharmacological potentiation restrains allergic airway inflammation, indicating that ion transport and cellular stress pathways intersect with IL-13 regulation. Additionally, noncoding RNAs including Linc00632 and miR-16 provide post-transcriptional brakes by inhibiting NF-κB signaling and mucus production.
negative regulation of interleukin-13 production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CFTR | Cystic fibrosis, allergic airway inflammation | CFTR knockout and potentiator-treated Th2 cells |
| CISH | Eosinophilic inflammation, lung fibroblast activation | CISH knockout lung fibroblasts |
| Linc00632 | Nasal epithelial inflammation, mucus hypersecretion | Linc00632 overexpression in nasal epithelial cells |
| miR-16 | Asthma, NF-κB-driven inflammation | miR-16 mimic/inhibitor in airway epithelial cells |
| IL13 | Atopic dermatitis, asthma | IL13 knockout or knock-in reporter mice |
Asthma and allergic airway inflammation
IL-13 is a key driver of airway hyperresponsiveness, mucus hypersecretion, and eosinophilic inflammation in asthma. Negative regulators such as CFTR and miR-16 restrain these processes; CFTR potentiation reduces allergic airway inflammation in models, and miR-16 suppresses IL-13-induced cytokine secretion and mucus production in nasal epithelial cells. Linc00632 similarly inhibits IL-13-induced inflammatory cytokine and mucus production, highlighting therapeutic potential.
Atopic dermatitis and psoriasis
Type 2 cytokines including IL-13 contribute to the pathogenesis of atopic dermatitis, and epidermal scratch injury can exacerbate both atopic dermatitis and psoriasis. Mast cells produce and respond to IL-13, amplifying itch and inflammation. Enhancing negative regulation of IL-13 production could therefore alleviate skin inflammation and reduce scratch-induced flares.
Cystic fibrosis and Th2 skewing
CFTR dysfunction is associated with exaggerated Th2 responses, and CFTR negatively reprograms Th2 cells; CFTR potentiators restrain allergic airway inflammation. This suggests that negative regulation of IL-13 production is impaired in cystic fibrosis, contributing to airway pathology. Modulating CFTR activity may restore control of IL-13 production.
B cell and IgE-mediated allergy
Human B lymphocytes synthesize IL-13, which regulates IgE production, linking negative regulation of IL-13 production to allergic sensitization. Dysregulated B cell IL-13 production could contribute to elevated IgE and atopic disease. Targeting negative regulators in B cells may offer a strategy to limit IgE-mediated pathology.
From negative regulation of interleukin-13 production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene increase IL-13 production? | CRISPR knockout in Th2 cells or mast cells |
| Does a point mutation in CFTR alter Th2 reprogramming? | CRISPR point mutation knock-in in primary T cells |
| Can a tagged allele track IL-13 secretion? | Knock-in of fluorescent tag at IL13 locus |
| Does overexpression of Linc00632 suppress IL-13-induced mucus? | Lentiviral overexpression in nasal epithelial cells |
| Does miR-16 mimic reduce NF-κB activation? | miRNA mimic transfection in airway epithelial cells |
| Does CISH feedback limit CCL26 production? | CISH knockout or overexpression in lung fibroblasts |
How to Study the negative regulation of interleukin-13 production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | IL-13 protein concentration | Supernatants from activated Th2 cells |
| Flow cytometry | Intracellular IL-13 and cell identity | Mast cell and B cell responses |
| RNA-seq | Transcriptome including IL13, CCL26, MUC5AC | Airway epithelial cells and fibroblasts |
| Small RNA-seq | miRNA expression profiles | Identification of miR-16-like regulators |
| CRISPR knockout | Gene function loss | Candidate negative regulator validation |
| CRISPR knock-in | Tagged or mutant alleles | Tracking IL-13 secretion or CFTR mutants |
| Western blot | NF-κB, STAT6, mTORC1-Atf4 signaling | Pathway analysis after perturbation |
| Luciferase reporter | Promoter activity of IL13 or target genes | Transcriptional regulation studies |
Cytokine quantification assays
ELISA and Luminex assays measure IL-13 protein levels in culture supernatants from activated Th2 cells, mast cells, or B lymphocytes. These methods are essential to confirm whether a genetic perturbation alters IL-13 production. Intracellular cytokine staining with flow cytometry can identify which cell types contribute to IL-13 output.
Transcriptional and post-transcriptional profiling
RNA-seq and qPCR quantify IL13 mRNA and related genes such as CCL26 and MUC5AC. Noncoding RNA studies use small RNA-seq or lncRNA arrays to identify regulators like miR-16 and Linc00632. These approaches reveal whether negative regulation occurs at the level of transcription or mRNA stability.
CRISPR-based functional genomics
CRISPR knockout, point mutation, knock-in, and overexpression screens can systematically test candidate genes for their ability to negatively regulate IL-13 production. Pooled screens with IL-13 reporter cells enable high-throughput discovery of regulators. Validated hits can be studied in primary human Th2 cells or cell lines.
Signaling pathway analysis
Western blot and phospho-flow cytometry assess NF-κB, STAT6, and mTORC1-Atf4 pathway activity following genetic manipulation. These methods link negative regulators to specific signaling nodes. Imaging of NF-κB nuclear translocation can provide spatial and temporal resolution.
How CRISPR Can Be Used to Study GO:0032696 negative regulation of interleukin-13 production
Knockout
CRISPR knockout is used to delete candidate negative regulators such as CISH, CFTR, or Linc00632 to test whether their loss increases IL-13 production. Knockout Th2 cells or mast cells can be stimulated and IL-13 measured by ELISA. This approach provides causal evidence for a gene's role in GO:0032696.
Point Mutation
Point mutations can model disease-associated variants in genes like CFTR that affect Th2 reprogramming and IL-13 regulation. CRISPR base editing or homology-directed repair introduces specific amino acid changes to dissect domain functions. Such models are valuable for understanding how subtle genetic changes alter negative regulation.
Knock-in
Knock-in of fluorescent or epitope tags at the IL13 locus enables real-time tracking of IL-13 production and secretion. Tagged knock-in of regulatory genes can also reveal localization and interaction partners. These models are particularly useful for imaging and proteomic studies.
Overexpression
Overexpression of negative regulators such as Linc00632 or miR-16 can suppress IL-13-induced inflammatory cytokines and mucus production. CRISPR activation (CRISPRa) or lentiviral overexpression allows gain-of-function studies. This approach helps identify therapeutic candidates that boost negative regulation.
How EDITGENE Supports negative regulation of interleukin-13 production Research
Researchers studying negative regulation of interleukin-13 production-related genes often need to determine whether a candidate gene is causally involved in dampening IL-13 output or is merely correlated with it. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models that answer these questions with rigor and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of interleukin-13 production research.
Frequently Asked Questions About negative regulation of interleukin-13 production
What is GO:0032696?
GO:0032696 is the Gene Ontology term for negative regulation of interleukin-13 production, describing any process that stops, prevents, or reduces the frequency, rate, or extent of IL-13 production.
What genes are involved in negative regulation of interleukin-13 production?
Key genes include CISH, CFTR, Linc00632, and miR-16, which act through feedback, ion channel, and noncoding RNA mechanisms.
How is IL-13 production negatively regulated in asthma?
In asthma, negative regulators such as CFTR and miR-16 dampen Th2 responses and IL-13-induced mucus production, limiting airway inflammation.
What diseases are linked to impaired negative regulation of IL-13 production?
Asthma, atopic dermatitis, psoriasis, and cystic fibrosis-related airway inflammation are associated with dysregulated IL-13 production.
Which cell types produce IL-13?
IL-13 is produced by Th2 cells, mast cells, and B lymphocytes, among others.
How can CRISPR be used to study negative regulation of IL-13 production?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in immune and epithelial cells.
What is the role of CISH in IL-13 regulation?
CISH is a negative regulator of IL-13-induced CCL26 production in lung fibroblasts, providing feedback control of eosinophil recruitment.
Does CFTR affect IL-13 production?
CFTR negatively reprograms Th2 cell responses, and CFTR potentiation restrains allergic airway inflammation, indicating a role in IL-13 regulation.
What methods measure IL-13 production?
ELISA, flow cytometry, RNA-seq, and reporter assays are commonly used to quantify IL-13 production and related gene expression.
Why is negative regulation of IL-13 production important for drug discovery?
Enhancing endogenous brakes on IL-13 production could treat type 2 inflammatory diseases without broad immunosuppression.
Conclusion
GO:0032696, negative regulation of interleukin-13 production, is a critical biological process that restrains type 2 inflammation. Key regulators such as CISH, CFTR, Linc00632, and miR-16 provide multiple layers of control, and their dysfunction contributes to asthma, atopic dermatitis, and cystic fibrosis-related pathology. CRISPR-based models are indispensable for dissecting these mechanisms and identifying therapeutic targets. EDITGENE offers end-to-end services to accelerate this research, from knockout and knock-in cell lines to library screening and bioinformatics.
References
- 1. Wathieu C et al.. 2024. Loss of Elp3 blocks intestinal tuft cell differentiation via an mTORC1-Atf4 axis.. EMBO J 43(18):3916-3947 PMID: 39085648
- 2. Takeshima H et al.. 2019. CISH is a negative regulator of IL-13-induced CCL26 production in lung fibroblasts.. Allergol Int 68(1):101-109 PMID: 30197185
- 3. Hajoui O et al.. 2004. Synthesis of IL-13 by human B lymphocytes: regulation and role in IgE production.. J Allergy Clin Immunol 114(3):657-63 PMID: 15356573
- 4. Rusznak M et al.. 2025. CFTR negatively reprograms Th2 cell responses, and CFTR potentiation restrains allergic airway inflammation.. JCI Insight 10(9) PMID: 40131363
- 5. Yue L et al.. 2020. Long Noncoding RNA Linc00632 Inhibits Interleukin-13-Induced Inflammatory Cytokine and Mucus Production in Nasal Epithelial Cells.. J Innate Immun 12(1):116-128 PMID: 31315126
- 6. McLeod JJ et al.. 2015. Mast cell production and response to IL-4 and IL-13.. Cytokine 75(1):57-61 PMID: 26088754
- 7. Furue K et al.. 2020. Pathogenic implication of epidermal scratch injury in psoriasis and atopic dermatitis.. J Dermatol 47(9):979-988 PMID: 32677165
- 8. Gao Y et al.. 2018. MicroRNA‑16 inhibits interleukin‑13‑induced inflammatory cytokine secretion and mucus production in nasal epithelial cells by suppressing the IκB kinase β/nuclear factor‑κB pathway.. Mol Med Rep 18(4):4042-4050 PMID: 30132525
